Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 3:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Metastatic Castration Resistant Prostate Cancer, Metastatic Cancer, Solid Tumor
Interventions
Nivolumab, Ipilimumab
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
8
States / cities
San Diego, California • San Francisco, California • Tampa, Florida + 5 more
Conditions
Solid Malignancies, Non-Hodgkin's Lymphoma
Interventions
AQ4N
Drug
Lead sponsor
Novacea
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
The Bronx, New York • San Antonio, Texas
Conditions
Prostate Cancer
Interventions
Talazoparib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
42
States / cities
Tempe, Arizona • Duarte, California • Lancaster, California + 23 more
Conditions
Prostate Cancer
Interventions
BMTP-11
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
1
States / cities
Houston, Texas
Conditions
Prostatic Neoplasms
Interventions
Enzalutamide, NSAA, LHRHA or Surgical Castration
Drug
Lead sponsor
University of Sydney
Other
Eligibility
18 Years and older · Male only
Enrollment
1,125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Nivolumab, Radium-223
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older · Male only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Salt Lake City, Utah
Conditions
Prostate Cancer
Interventions
therapeutic autologous dendritic cells
Biological
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Metastatic Prostate Cancer
Interventions
Dasatinib, Docetaxel
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older · Male only
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Chicago, Illinois • Springfield, Illinois • Nyack, New York + 2 more
Conditions
Metastatic Prostate Cancer
Interventions
ARX517, Apalutamide, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Conditions
Prostatic Neoplasms
Interventions
Atrasentan
Drug
Lead sponsor
Abbott
Industry
Eligibility
19 Years and older · Male only
Enrollment
941 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
94
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 73 more
Conditions
Metastatic Castration-Resistant Prostate Cancer, Metastatic Breast Cancer, Non-small Cell Lung Cancer, Advanced Solid Tumors
Interventions
CCS1477, Abiraterone acetate, Enzalutamide, Darolutamide, Olaparib, Atezolizumab
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Completed Phase 2 Interventional Results available

Abemaciclib With or Without Atezolizumab for mCRPC

NCT04751929
Conditions
Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
Interventions
Abemaciclib, Atezolizumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Metastatic Prostate Cancer, Prostatic Neoplasms, Prostate Cancer, Prostatic Cancer, Prostate Neoplasms
Interventions
18F-NaF, 18F-DCFPyL, 18F-FDG
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Male only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Solid Tumor
Interventions
Rucaparib
Drug
Lead sponsor
pharmaand GmbH
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
19
States / cities
Los Angeles, California • San Francisco, California • Fort Myers, Florida + 15 more
Completed Phase 2 Interventional Results available

EXTEND Exercise Trial

NCT02256111
Conditions
Non-metastatic, Hormone naïve Prostate Cancer
Interventions
Enzalutamide, Androgen deprivation therapy, Supervised exercise training
Drug · Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years and older · Male only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
2
States / cities
New York, New York • Durham, North Carolina
Conditions
Prostate Cancer
Interventions
Cabozantinib, Androgen Ablation Therapy
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Male only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Conditions
Castrate Resistent Prostate Cancer
Interventions
BPX-201 vaccine plus AP1903
Biological
Lead sponsor
Bellicum Pharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Birmingham, Alabama • Dallas, Texas
Conditions
Prostate Cancer
Interventions
Immunotherapy allogeneic GM-CSF secreting cellular vaccine
Biological
Lead sponsor
Cell Genesys
Industry
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
12
States / cities
Laguna Woods, California • San Francisco, California • Tarzana, California + 8 more
Conditions
Prostate Cancer Metastatic
Interventions
ODM-208, Midazolam
Drug
Lead sponsor
Orion Corporation, Orion Pharma
Industry
Eligibility
18 Years and older · Male only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
4
States / cities
Baltimore, Maryland • Minneapolis, Minnesota • Omaha, Nebraska + 1 more
Conditions
Vertebral Metastasis
Interventions
Conformal High Dose Intensity Modulated Radiation Therapy
Radiation
Lead sponsor
Ronald McGarry
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Completed Not applicable Interventional Accepts healthy volunteers

The BurnAlong Pilot Study for Adolescent and Young Adult Cancer Survivors

NCT05131815
Conditions
Cancer, Cancer Metastatic, Neoplasms, Breast Cancer, Lung Cancer, Thyroid Cancer, Lymphoma, Lymphoma, Non-Hodgkin, Hodgkin Lymphoma, Leukemia, Sarcoma, Skin Cancer, Bone Cancer, Gynecologic Cancer, Pancreas Cancer, Multiple Myeloma, Colorectal Cancer, Gastrointestinal Cancer, Prostate Cancer, Glioblastoma, Brain Cancer, Head and Neck Cancer
Interventions
Virtual group based physical activity (BurnAlong) and Social Media Discussion Board
Behavioral
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 39 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Prostate Cancer, Prostate Cancer Metastatic
Interventions
Questionnaires
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Minutes and older · Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
3'-Deoxy-3'-[18F]-fluorothymidine, Chemical-shift-encoded MRI
Drug · Device
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Madison, Wisconsin
Conditions
Prostate Cancer
Interventions
Zytiga® (Abiraterone Acetate), SoluMatrix™ (Abiraterone Acetate)
Drug
Lead sponsor
Sun Pharmaceutical Industries Limited
Industry
Eligibility
18 Years and older · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
17
States / cities
Laguna Hills, California • Los Angeles, California • San Bernardino, California + 14 more